Candel Therapeutics (CADL) R&D Day 2025 summary

Pipeline overview and program updates

• CAN-2409 is the lead asset, positioned as a pan-solid tumor immunotherapy with positive phase III data in localized prostate cancer, over 1,000 patients dosed, and promising results in pancreatic and non-small cell lung cancers.

• CAN-3110, a next-generation replication-competent oncolytic HSV, shows encouraging survival and immune activation in recurrent high-grade glioma, with potential for broader application in nestin-expressing tumors.

• R&D Day will feature updates on viral immunotherapy platforms and the oncology pipeline, including CAN-2409 and CAN-3110.

• Financially, $87M in cash and a $130M term loan provide runway into Q1 2027, supporting ongoing and future trials.

Clinical trial data and development milestones

• CAN-2409 met its primary endpoint in a 745-patient phase III prostate cancer trial, showing a 30% reduction in disease recurrence and strong secondary endpoint support.

• CAN-2409 completed phase 2a trials in NSCLC and PDAC, and a pivotal phase 3 trial in localized prostate cancer under FDA Special Protocol Assessment.

• CAN-3110 demonstrated improved median overall survival in recurrent glioblastoma compared to historical controls, with initial results published in Nature and ongoing studies exploring multiple injections and immune biomarkers.

• Updated clinical data for non-small cell lung cancer and prostate cancer are expected in the next two quarters, with a pivotal phase III lung cancer trial to start in Q2 next year.

R&D strategy and innovation priorities

• enLIGHTEN Discovery Platform leverages HSV-based technology and advanced analytics to create new viral immunotherapies for solid tumors.

• Emphasis on experimental medicine trials to rapidly assess efficacy and inform larger studies.

• Deep biomarker research and integration of precision/stratified medicine approaches guide future trial design and potential label expansion.

• Focus on combination therapies and early disease intervention, leveraging immunogenic cell death and in situ vaccination concepts.